Company
Vandria
We are developing first-in-class small molecules against a novel target to improve mitochondrial function and reduce chronic inflammation to treat age-related diseases.
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Headquarters
- Lausanne, Switzerland
- Founded
- 2021
Claim, correct or request removal
Record updated 28 September 2026
About
Vandria is a clinical stage biotech company developing first-in-class small molecules against a novel target to restore mitochondrial function and reduce inflammation for the treatment of age-related and chronic diseases.
Funding snapshot
- Total raised
- $51.3MSum of rounds, as of 2026-09-18Source (opens in a new tab)
- Latest round
- Series A, $30.7M2024-08-21
Funding rounds
- Series A
- $30.7M2024-08-21, Company stated
- Grant
- 2024-02-08
- Series A
- $20.6M2023-12-14, Company stated
Loading relationship preview